Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Dec 27, 2022 3:13pm
154 Views
Post# 35192707

RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates interferon (IFN) signalling

RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates interferon (IFN) signallingCARs initiate robust T cell activation and subsequent cytolytic killing of the target cell through an intracelluar signaling domain.. Utilizing T cells expressing chimeric antigen receptors (CARs) to identify and attack solid tumors has proven challenging, in large part because of the lack of tumor-specific targets to direct CAR bindingTumor selectivity is crucial because on-target, off-tumor activation of CAR T cells can result in a loss of efficacy and potentially lethal toxicities. 

Along with what has been already posted regarding ONCY's pelareorep ability to down-regulate HIF-1alpha, coating CAR-T cells with pelareorep for intravenous administration results in pelareorep's further ability to present "pelareorep labeled" tumor-specific targets for direct CAR binding in solid tumors, thus avoiding off-target activation of CAR-T cells, increased treatmdnt efficacy and the avoidance of lethal toxciites that CAR-T cells have otherwise been known for.
<< Previous
Bullboard Posts
Next >>